Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture

Annals of the New York Academy of Sciences

Volumn 1085, Issue , 2006, Pages 39-46

  Rentschler, Mark ^a   Baxter, B Timothy ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Aneurysm; Tetracycline

Indexed keywords

CHOLESTEROL; DOXYCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; PROPRANOLOL; PROTEINASE;

ABDOMINAL AORTA ANEURYSM; ANEURYSM RUPTURE; ATHEROSCLEROSIS; CONFERENCE PAPER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PROTEIN EXPRESSION; QUALITY OF LIFE; AORTA RUPTURE; ARTICLE; TIME;

ANIMALIA;

AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; DOXYCYCLINE; HUMANS; TIME FACTORS;

EID: 34147194346     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1383.003     Document Type: Conference Paper

References (21)

1. NATIONAL CENTER FOR HEALTH STATISTICS. 2002. Deaths, percent of total deaths, and death rates for the 10 leading causes of death in selected age groups, by race and sex: United States, 2000. National Vital Statistics Report. Accessed at www.cdc.gov/nchs/ fastats/pdf/nvsr50 16t1.pdf on 15 November 2004.
2. LEDERLE, F.A., J.T. POWELL & R.M. GREENHALGH. 2006. Repair of small abdominal aortic aneurysms. N. Engl. J. Med. 354: 1537-1538.
3. FLEMING, C., E.P. WHITLOCK, T.L. BEIL & F.A. LEDERLE. 2005. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 142: 203-211.
4. BRADY, A.R., S.G. THOMPSON, F.G. FOWKES, et al. 2004. UK Small Aneurysm Trial Participants. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 110: 16-21.
5. LINDHOLT, J.S., S. VAMMEN, H. FASTING & E.W. HENNEBERG. 2000. Psychological consequences of screening for abdominal aortic aneurysm and conservative treatment of small abdominal aortic aneurysms. Eur. J. Vasc. Endovasc. Surg. 20: 79-83.
6. CAO, P., CAESAR TRIAL COLLABORATORS. 2005. Comparison of Surveillance vs. Aortic Endografting for Small Aneurysm Repair (CAESAR) trial: study design and progress. Eur. J. Vasc. Endovasc. Surg. 30: 245-251.
7. BERTGES, D.J., R.M. ZWOLAK, D.H. DEATON, et al. 2003. Current hospital costs and medicare reimbursement for endovascular abdominal aortic aneurysm repair. J. Vasc. Surg. 37: 272-279.
8. MILLONIG, G., G.T. MALCOM & G. WICK. 2002. Early inflammatory-immunological lesions in juvenile atherosclerosis from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY)-study. Atherosclerosis. 160: 441-448.
9. SHAPIRO, S.D., S.K. ENDICOTT, M.A. PROVINCE, et al. 1991. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. J. Clin. Invest. 87: 1828-1834.
10. LONGO, G.M., W. XIONG, T.C. GREINER, et al. 2002. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 110: 625-632.
11. PYO, R., J.K. LEE, J.M. SHIPLEY, et al. 2000. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest. 105: 1641-1649.
12. YOSHIMURA, K., H. AOKI, Y. IKEDA, et al. 2005. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat. Med. 11: 1330-1338.
13. GOLUB, L.M., M. WOLFF, H.M. LEE, et al. 1985. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J. Periodontal Res. 20: 12-23.
14. PETRINEC, D., S. LIAO, D.R. HOLMES, et al. 1996. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 23: 336-346.
15. PRALL, A.K., G.M. LONGO, W.G. MAYHAN, et al. 2002. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J. Vasc. Surg. 35: 923-929.
16. CURCI, J.A., D. MAO, D.G. BOHNER, et al. 2000. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J.Vasc. Surg. 31: 325-342.
17. MOSORIN, M., J. JUVONEN, F. BIANCARI, et al. 2001. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J. Vasc. Surg. 34: 606-610.
18. EVAR TRIAL PARTICIPANTS. 2005. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. Lancet. 365: 2187-2192.
19. PROPANOLOL ANEURYSM TRIAL I NVESTIGATORS. 2002. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J.Vasc. Surg. 35: 72-79.
20. LINDHOLT, J.S., E.W. HENNEBERG, S. JUUL & H. FASTING. 1999. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int. Angiol. 18: 52-57.
21. HABASHI, J.P., D.P. JUDGE, T.M. HOLM, et al. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 312: 117-121.